目的:研究应用奥美拉唑与瑞巴派特联合治疗活动期胃溃疡的疗效。方法:选取2013年6月到2015年6月间来奉化市中医医院接诊的82例胃溃疡患者为研究对象,采取随机数字法将其分为对照组和观察组,其中对照组40例,患者使用奥美拉唑进行治疗,观察组42例,患者联合应用奥美拉唑与瑞巴派特,研究和记录分析两组患者的临床疗效,结果:在观察组患者中,有16例患者治愈,占39.62%,5例患者治疗无效,占11.90%,其治疗总有效率占85.71%。而在对照组中,有9例患者治愈,占22.64%,治疗无效有14例,占35%,其治疗总有效率为62.50%,观察组的总有效率明显高于对照组,差异比较,有统计学意义。而且观察组在炎症细胞程度、黏膜形态结构、中性黏液含量三个方面与对照组而言,评分均较优,差异有统计学意义(P<0.05)。并且对两组患者的胃黏膜损伤程度评估所得:观察组损伤率明显低于对照组,差异有统计学意义(P<0.05)。结论:与仅使用奥美拉唑比较,对活动期胃溃疡患者联合使用奥美拉唑与瑞巴派特进行治疗,可取得更好的临床疗效和高的愈合率,可以更好地改善胃溃疡患者的临床症状。 Objective: To study the application of omeprazole combined with rebamipide in the treatment of active gastric ulcer. Methods: From August 2013 to June 2015, 82 patients with gastric ulcer admitted to Fenghua Hospital of Traditional Chinese Medicine were enrolled in this study. The patients were divided into control group and observation group by random number method, including 40 cases in control group, The patients were treated with omeprazole. The observation group consisted of 42 patients who were treated with omeprazole and rebamipide. The clinical efficacy of the two groups was studied and recorded. Results: In the observation group, 16 patients Cured, accounting for 39.62%, 5 patients ineffective treatment, accounting for 11.90%, the total effective rate of treatment accounted for 85.71%. In the control group, 9 patients were cured, accounting for 22.64%, 14 cases were ineffective, accounting for 35% of the total effective rate was 62.50%, the total effective rate was significantly higher in the observation group than in the control group, There is statistical significance. And the observation group in the degree of inflammatory cells, mucosal morphology, the neutral mucus content of the three aspects compared with the control group, the score was better, the difference was statistically significant (P <0.05). And the gastric mucosal lesions in both groups were evaluated: the damage rate in the observation group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). CONCLUSIONS: Omeprazole and rebamipide are more effective than omeprazole in the treatment of patients with active gastric ulcer, which results in better clinical outcomes and higher rates of healing and better gastric Clinical symptoms of ulcer patients.